#United States #Franklin Lakes #BD Becton Dickinson Liverty

BD Introduces the Liverty™ TIPS Stent Graft for Portal Hypertension

BD (Becton, Dickinson and Company) has recently announced the approval of its next-generation Liverty™ TIPS Stent Graft, marking a notable milestone in the treatment of portal hypertension throughout the European Union. This innovative device is designed to enhance treatment options for patients suffering from advanced liver diseases, particularly those facing complications arising from cirrhosis and portal hypertension.

A Growing Health Challenge

Cirrhosis affects an estimated 58 million people globally, contributing to various life-threatening complications, including portal hypertension, which can lead to serious health issues like variceal bleeding and fluid accumulation in the abdomen or chest. TIPS (transjugular intrahepatic portosystemic shunt) procedures play a crucial role in alleviating these symptoms by reducing portal pressure and improving blood circulation.

Key Features of the Liverty™ TIPS Stent Graft

The Liverty™ TIPS Stent Graft distinguishes itself in the medical technology landscape with its adjustable inner diameter ranging from 6 to 10 mm, along with the widest variety of covered TIPS stent lengths on the market. The device is engineered with a flexible, self-expanding nitinol frame coupled with dual-layer ePTFE encapsulation. This enhanced design includes a carbon-impregnated inner surface, ensuring superior performance. It is also delivered through a triaxial delivery system, which significantly enhances placement accuracy and user control.

According to Rima Alameddine, the worldwide president of Peripheral Intervention at BD, safe and effective treatment options are essential for patients dealing with complications from portal hypertension. She expressed optimism about the capabilities of the Liverty™ Stent Graft to assist healthcare professionals in personalizing therapy, potentially leading to improved long-term outcomes for patients.

Clinical Insights and Future Presentations

The efficacy and safety of the Liverty™ TIPS Stent Graft were assessed in the pivotal ARCH clinical trial, which is a global, multi-center, and single-arm study focusing on the treatment of portal hypertension complications. The groundbreaking data from this trial will be highlighted on April 12, 2026, during the Society of Interventional Radiology (SIR) Annual Scientific Meeting, presented by Global Principal Investigator Prof. Ziv Haskal, MD.

Dr. Haskal noted that the Liverty™ TIPS Stent Graft represents a significant development in managing patients with serious portal hypertension complications. Its customizable diameter and innovative delivery system enable physicians to tailor the shunt to the individual needs of each patient, making it a vital tool in modern interventional radiology.

BD’s Commitment to Healthcare Advancement

As one of the largest medical technology companies globally, BD is dedicated to advancing healthcare through innovative solutions and technologies. By leveraging cutting-edge research and development efforts, the company aims to optimize clinical operations and improve patient care.

BD operates in over 50 countries, employing more than 60,000 individuals, and produces billions of medical products annually. Their collaboration with healthcare providers ensures effective solutions that enhance patient outcomes, streamline costs, and widen access to essential healthcare services.

The Liverty™ TIPS Stent Graft not only represents a leap in technology but also underscores BD’s commitment to addressing critical healthcare challenges. As they introduce this innovative device to the European market, the company continues to pave the way for advanced treatments in liver disease management.

For more details about BD and their products, please visit bd.com or connect with them on social media platforms including LinkedIn and Instagram.